AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29374658 — intervention group
Group type: COMPARATOR
Intervention: 2.5-year image-read, liquid-based cytology (LBC) screening with HPV triage of low-grade smears (active control Arm A)
Number of subjects: 121000
Study 29374658 — intervention group
Group type: EXPERIMENTAL
Intervention: LBC or dual-stained (p16INK4a and Ki-67) cytology testing (dual-stained cytology)
Number of subjects: 121000
Study 27648523 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus (EVR) + mycophenolic acid (MPA)
Number of subjects: 71
Study 27648523 — intervention group
Group type: COMPARATOR
Intervention: tacrolimus (TAC) + MPA
Number of subjects: 71
Study 25439417 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of intravenous (IV) melatonin
Number of subjects: 44
Study 25439417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 22423090 — intervention group
Group type: EXPERIMENTAL
Intervention: Local energy model of pooling based on estimated receptive fields
Number of subjects: 0
Study 22423090 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral responses to global stimuli
Number of subjects: 0
Study 19342389 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniaturized closed circuit CPB with the maquet‐cardiopulmonary MECC System (study group, n=60)
Number of subjects: 120
Study 19342389 — intervention group
Group type: COMPARATOR
Intervention: Standard CPB (control group, n=60)
Number of subjects: 120
Study 16884468 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 1250
Study 14722678 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET delayed imaging
Number of subjects: 36
Study 14722678 — intervention group
Group type: COMPARATOR
Intervention: MRI/CT
Number of subjects: 36
Study 14722678 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET delayed imaging (retrospective evaluation with standardized uptake ratio)
Number of subjects: 36
Study 11851748 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A)
Number of subjects: 0
Study 11851748 — intervention group
Group type: COMPARATOR
Intervention: Serial casting
Number of subjects: 0
Study 11851748 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) for hemiplegia
Number of subjects: 0
Study 11851748 — intervention group
Group type: COMPARATOR
Intervention: Serial casting for hemiplegia
Number of subjects: 0
Study 11851748 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) for diplegia
Number of subjects: 0
Study 11851748 — intervention group
Group type: COMPARATOR
Intervention: Serial casting for diplegia
Number of subjects: 0
Study 9457389 — intervention group
Group type: EXPERIMENTAL
Intervention: rIL-2 plus IFN-alpha plus cisplatin
Number of subjects: 0
Study 9457389 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacarbazine plus cisplatin plus IFN-alpha plus rIL-2
Number of subjects: 0
Study 9457389 — intervention group
Group type: COMPARATOR
Intervention: rIL-2 and/or IFN-alpha
Number of subjects: 0
Study 7619241 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselor group (N = 59)
Number of subjects: 102
Study 3163527 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel (1% applied interdentally 4 times/year)
Number of subjects: 220
Study 3163527 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo gel (applied interdentally 4 times/year)
Number of subjects: 220
Study 3163527 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 220
Study 31150753 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial family treatments during the first 9 months of the study
Number of subjects: 144
Study 31150753 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline medication exposure
Number of subjects: 144
Study 31150753 — intervention group
Group type: EXPERIMENTAL
Intervention: More severe baseline depressive symptoms, suicidality, lower quality of life scores, and minority race/ethnicity
Number of subjects: 144
Study 29526844 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (ET) - 8 weeks of running on treadmill at 60‐75% of VO2peak, 3 sessions per week
Number of subjects: 20
Study 29526844 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (ET)
Number of subjects: 20
Study 29526844 — intervention group
Group type: COMPARATOR
Intervention: Control (CONT) - no exercise training
Number of subjects: 20
Study 28266150 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcatheter-assisted trabeculotomy
Number of subjects: 62
Study 28266150 — intervention group
Group type: COMPARATOR
Intervention: Rigid probe trabeculotomy
Number of subjects: 62
Study 25230094 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (afamelanotide + NB‐UV‐B)
Number of subjects: 55
Study 25230094 — intervention group
Group type: COMPARATOR
Intervention: NB‐UV‐B monotherapy
Number of subjects: 55
Study 24444682 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 178
Study 24444682 — intervention group
Group type: COMPARATOR
Intervention: Parenteral Nutrition (PN)
Number of subjects: 178
Study 24444682 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EN and PN
Number of subjects: 178
Study 21075452 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light treatment (BLT) for 6 weeks (10,000 lux, 30 min daily)
Number of subjects: 24
Study 21075452 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 24
Study 18176328 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipranavir boosted with ritonavir (TPV/r)
Number of subjects: 315
Study 18176328 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipranavir boosted with ritonavir (TPV/r) added to dual-boosted regimens (LPV, SQV, APV)
Number of subjects: 315
Study 18176328 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual PI regimen with TPV
Number of subjects: 315
Study 17079856 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0
Study 17079856 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoids
Number of subjects: 0
Study 15330032 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-coated pins
Number of subjects: 23
Study 15330032 — intervention group
Group type: COMPARATOR
Intervention: Uncoated pins
Number of subjects: 23
Study 11783075 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy
Number of subjects: 56
Study 11783075 — intervention group
Group type: COMPARATOR
Intervention: Intravenous chemotherapy
Number of subjects: 56
Study 9018028 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release carbidopa/levodopa (Sinemet CR 50/200)
Number of subjects: 618
Study 9018028 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release carbidopa/levodopa (Sinemet 25/100)
Number of subjects: 618
Study 9018028 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment regimens
Number of subjects: 618
Study 8343245 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 40
Study 8343245 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 40
Study 3829588 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltotriose
Number of subjects: 0
Study 3829588 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose oligomer mixture
Number of subjects: 0
Study 3829588 — intervention group
Group type: COMPARATOR
Intervention: 70 mmol/l sucrose
Number of subjects: 0
Study 3829588 — intervention group
Group type: COMPARATOR
Intervention: 140 mmol/l glucose
Number of subjects: 0
Study 31762043 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive school-based physical activity program (CSPAP)
Number of subjects: 3294
Study 30958052 — intervention group
Group type: EXPERIMENTAL
Intervention: 11+ Kids intervention
Number of subjects: 31
Study 30958052 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual warm-up)
Number of subjects: 31
Study 28108537 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT levels of 9-13 ng/L
Number of subjects: 8153
Study 28108537 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT levels of ≥14 ng/L
Number of subjects: 8153
Study 28108537 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT levels >8 ng/L
Number of subjects: 8153
Study 28108537 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT added to fully adjusted models including glucose
Number of subjects: 8153
Study 28108537 — intervention group
Group type: COMPARATOR
Intervention: hs-cTnT levels ≤5 ng/L
Number of subjects: 8153
Study 26291092 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment for PAH
Number of subjects: 2762
Study 26291092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2762
Study 23147520 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice daily for 4 weeks
Number of subjects: 599
Study 23147520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 599
Study 21296237 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted elimination diet for 5 weeks
Number of subjects: 100
Study 21296237 — intervention group
Group type: COMPARATOR
Intervention: Instructions for a healthy diet (control group)
Number of subjects: 100
Study 21296237 — intervention group
Group type: EXPERIMENTAL
Intervention: Food challenge phase with high-IgG or low-IgG foods
Number of subjects: 100
Study 21296237 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-specific IgG levels at baseline
Number of subjects: 100
Study 21296237 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenge phase
Number of subjects: 100
Study 19169168 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g of soy protein with 90 mg of isoflavones
Number of subjects: 203
Study 19169168 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g of soy protein without isoflavones
Number of subjects: 203
Study 19169168 — intervention group
Group type: COMPARATOR
Intervention: 25 g of milk protein (casein and whey)
Number of subjects: 203
Study 19169168 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical performance measurements
Number of subjects: 203
Study 17061459 — intervention group
Group type: EXPERIMENTAL
Intervention: Omron M6 monitor (arm cuff, A/A, BHS validation)
Number of subjects: 152
Study 17061459 — intervention group
Group type: COMPARATOR
Intervention: Microlife BP-3AC1 monitor with MAM technology
Number of subjects: 152
Study 17061459 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both monitors
Number of subjects: 152
Study 15598483 — intervention group
Group type: EXPERIMENTAL
Intervention: 31 gauge x 6 mm needle
Number of subjects: 62
Study 15598483 — intervention group
Group type: COMPARATOR
Intervention: 29 gauge x 12.7 mm needle
Number of subjects: 62
Study 15598483 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter needle preference
Number of subjects: 62
Study 11431132 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing caloric intake to offset high energy demand
Number of subjects: 0
Study 11431132 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with exogenous estrogen
Number of subjects: 0
Study 11431132 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment aimed at correcting metabolic abnormalities
Number of subjects: 0
Study 9208356 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg daily for 3 months)
Number of subjects: 76
Study 9208356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 8215279 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly infusions of immune globulin at a dose of 500 mg/kg of body weight
Number of subjects: 49
Study 8215279 — intervention group
Group type: COMPARATOR
Intervention: No immune globulin (control group)
Number of subjects: 49
Study 2824045 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (CBDCA) 400 mg/m2 iv every 4 weeks until relapse
Number of subjects: 141
Study 2824045 — intervention group
Group type: COMPARATOR
Intervention: Iproplatin (CHIP) 270 mg/m2 iv every 4 weeks until relapse
Number of subjects: 141
Study 30629813 — intervention group
Group type: EXPERIMENTAL
Intervention: csDMARD
Number of subjects: 205
Study 30629813 — intervention group
Group type: COMPARATOR
Intervention: TNFi
Number of subjects: 205
Study 31547861 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy and 20% albumin
Number of subjects: 118
Study 31547861 — intervention group
Group type: COMPARATOR
Intervention: Phototherapy and saline
Number of subjects: 118
Study 28419398 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (Lucentis; Genentech) - first intravitreal injection
Number of subjects: 84
Study 25178900 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal baseline systolic blood pressure (SBP)
Number of subjects: 0
Study 25178900 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal SBP change during pregnancy
Number of subjects: 0
Study 25178900 — intervention group
Group type: EXPERIMENTAL
Intervention: Child's weight, baseline SBP, age, and sex
Number of subjects: 0
Study 23827398 — intervention group
Group type: EXPERIMENTAL
Intervention: primary angioplasty ± abciximab
Number of subjects: 1301
Study 23827398 — intervention group
Group type: EXPERIMENTAL
Intervention: MBG 0/1
Number of subjects: 1301
Study 23827398 — intervention group
Group type: COMPARATOR
Intervention: MBG
Number of subjects: 1301
Study 21067812 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant Behavioral Assessment and Intervention Program (IBAIP) - 6-8 home visits during the first 8 months after birth
Number of subjects: 78
Study 21067812 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 78
Study 19404172 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural steroid injections
Number of subjects: 29
Study 19404172 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient physical therapy program for 2 weeks
Number of subjects: 29
Study 19404172 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 29
Study 17498003 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 954
Study 15451124 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (TN) with intensive treatment
Number of subjects: 619
Study 15451124 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (TN)
Number of subjects: 619
Study 12053057 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (80 mg)
Number of subjects: 12
Study 12053057 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol (20 mg)
Number of subjects: 12
Study 12053057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9686464 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimsuit
Number of subjects: 72
Study 9686464 — intervention group
Group type: COMPARATOR
Intervention: Sweater
Number of subjects: 72
Study 8021483 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise three times a week at 70% maximum work capacity for 30 min
Number of subjects: 30
Study 8021483 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary modification to achieve weight loss involving 4200 kj/day dietary restriction
Number of subjects: 30
Study 8021483 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of exercise and dietary modification weight-loss programmes
Number of subjects: 30
Study 8021483 — intervention group
Group type: COMPARATOR
Intervention: Control period (no intervention)
Number of subjects: 30
Study 2478793 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimobendan (5 mg b.i.d.)
Number of subjects: 20
Study 2478793 — intervention group
Group type: COMPARATOR
Intervention: Captopril (25 mg t.i.d.)
Number of subjects: 20
Study 973004 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of prostaglandin F2alpha
Number of subjects: 40
Study 30782213 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine replacement therapy plus standard chronic heart failure treatment
Number of subjects: 0
Study 30782213 — intervention group
Group type: COMPARATOR
Intervention: Standard chronic heart failure therapy
Number of subjects: 0
Study 28494046 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant bed preparation before molar extractions
Number of subjects: 22
Study 28494046 — intervention group
Group type: COMPARATOR
Intervention: Implant bed preparation after molar extractions
Number of subjects: 22
Study 23981858 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive therapy (ICT)
Number of subjects: 29
Study 22345690 — intervention group
Group type: EXPERIMENTAL
Intervention: Sesame oil
Number of subjects: 30
Study 22345690 — intervention group
Group type: COMPARATOR
Intervention: Control oil
Number of subjects: 30
Study 21449921 — intervention group
Group type: EXPERIMENTAL
Intervention: scGOS/lcFOS/pAOS
Number of subjects: 113
Study 21449921 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 113
Study 19386081 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 134
Study 19386081 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 134
Study 16236380 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-food Mediterranean type diet rich in PAF antagonist
Number of subjects: 45
Study 16236380 — intervention group
Group type: COMPARATOR
Intervention: Regular diet
Number of subjects: 45
Study 15329300 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic category‐sorting task (Experiment 1)
Number of subjects: 0
Study 15329300 — intervention group
Group type: EXPERIMENTAL
Intervention: Category‐based inductive reasoning task (Experiment 2)
Number of subjects: 0
Study 11102252 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 920
Study 11102252 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy
Number of subjects: 920
Study 9294390 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (221 women) received a letter asking them to seek a Pap test and a reminder letter 4 weeks later.
Number of subjects: 441
Study 9294390 — intervention group
Group type: COMPARATOR
Intervention: Control group (220 women) received no letters.
Number of subjects: 441
Study 8328996 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (5 mg)
Number of subjects: 51
Study 8328996 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg)
Number of subjects: 51
Study 8328996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 3886498 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (2 X 325 mg every 4 h to total 8 tablets during the first 24 h)
Number of subjects: 90
Study 3886498 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (2 X 325 mg every 4 h to total 8 tablets during the first 24 h)
Number of subjects: 90
Study 3886498 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identically packaged, 2 X 325 mg every 4 h to total 8 tablets during the first 24 h)
Number of subjects: 90
Study 29797212 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin aspart (0.15 unit/kg every two hours)
Number of subjects: 50
Study 29797212 — intervention group
Group type: COMPARATOR
Intervention: Intravenous regular insulin (0.05-0.1 unit/kg/hour)
Number of subjects: 50
Study 27823994 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary vein technique
Number of subjects: 247
Study 27823994 — intervention group
Group type: COMPARATOR
Intervention: Subclavian vein technique
Number of subjects: 247
Study 24286360 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release melatonin 2 mg (CRM)
Number of subjects: 92
Study 24286360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 21862955 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 1009
Study 21862955 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 1009
Study 21862955 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 1009
Study 21862955 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 1009
Study 15863532 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous suture closure alone
Number of subjects: 280
Study 15863532 — intervention group
Group type: COMPARATOR
Intervention: Suture plus drain
Number of subjects: 280
Study 12195841 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation powder via Easyhaler (400 micrograms/day)
Number of subjects: 326
Study 12195841 — intervention group
Group type: COMPARATOR
Intervention: Budesonide inhalation powder via Turbuhaler (400 micrograms/day)
Number of subjects: 326
Study 12195841 — intervention group
Group type: EXPERIMENTAL
Intervention: Easyhaler
Number of subjects: 326
Study 12195841 — intervention group
Group type: COMPARATOR
Intervention: Turbuhaler
Number of subjects: 326
Study 9818662 — intervention group
Group type: EXPERIMENTAL
Intervention: Low calorie diet, appetite suppressant, nonsteroidal antiinflammatory drugs, and walking program for 6 weeks
Number of subjects: 22
Study 9818662 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking program
Number of subjects: 22
Study 9818662 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in percent body fat
Number of subjects: 22
Study 8580388 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 532
Study 8580388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 532
Study 2623218 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine needle aspiration biopsy
Number of subjects: 29
Study 2623218 — intervention group
Group type: COMPARATOR
Intervention: Fibreoptic bronchoscopy
Number of subjects: 29
Study 2623218 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall results for fine needle aspiration biopsy
Number of subjects: 29
Study 2623218 — intervention group
Group type: COMPARATOR
Intervention: Overall results for fibreoptic bronchoscopy
Number of subjects: 29
Study 321410 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (Ritalin)
Number of subjects: 1
Study 321410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 321410 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management
Number of subjects: 1
Study 29565769 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% O2 (hypoxic rest)
Number of subjects: 14
Study 29565769 — intervention group
Group type: COMPARATOR
Intervention: 21% O2 (normoxic rest)
Number of subjects: 14